ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,399.22
-0.51%
US Tech 100
18,352.00
-0.99%
Dow Jones
39,935.07
0.20%
Brent Oil
81.535
0.99%
Bitcoin
65,716.77
0.53%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aquestive Therapeutics Inc (AQST) Quote

Aquestive Therapeutics Inc

Aquestive Therapeutics Inc (AQST)

NASDAQ
3.45
0.08
(2.37%)
At close: July 25 4:00PM
Delayed by 15 minutes
3.46
0.01
( 0.29% )
After Hours: 5:35PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
3.46
Bid
3.45
Ask
3.49
Volume
1,914,847
3.26 Day's Range 3.58
1.2514 52 Week Range 6.23
Market Cap
314.993M
Previous Close
3.37
Open
3.47
Last Trade
4
@
3.49
Last Trade Time
18:26:24
Financial Volume
$ 6,570,469
VWAP
3.4313
Average Volume (3m)
1,308,090
Shares Outstanding
91,038,532
Dividend Yield
-
PE Ratio
-39.93
Earnings Per Share (EPS)
-0.09
Revenue
50.58M
Net Profit
-7.87M

About Aquestive Therapeutics Inc

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the t... Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.aquestive.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Aquestive Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AQST. The last closing price for Aquestive Therapeutics was $3.37. Over the last year, Aquestive Therapeutics shares have traded in a share price range of $ 1.2514 to $ 6.23.

Aquestive Therapeutics currently has 91,038,532 shares outstanding. The market capitalization of Aquestive Therapeutics is $306.80 million. Aquestive Therapeutics has a price to earnings ratio (PE ratio) of -39.93.

AQST Latest News

More News

Form 8-K - Current report

11 hours ago
Edgar (US Regulatory)

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome...

11 hours ago
GlobeNewswire Inc.

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...

July 23 2024
GlobeNewswire Inc.

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...

June 27 2024
GlobeNewswire Inc.

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm supportive clinical studies and expects to...

June 25 2024
GlobeNewswire Inc.

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...

June 18 2024
GlobeNewswire Inc.

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

June 12 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 11 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3410.89743589743.123.582.960414459563.21377109CS
41.0442.97520661162.423.582.3413049762.83230334CS
120.061.764705882353.43.62.2413080902.90488267CS
261.0543.56846473032.416.232.2420141783.80772293CS
521.9121.7948717951.566.231.251412035893.5052243CS
156-0.22-5.978260869573.686.40.6187632242.93172258CS
260-0.39-10.12987012993.85100.6187624153.9368163CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BFIBurgerFi International Inc
$ 0.4826
(126.47%)
17.38M
WINTWindtree Therapeutics Inc
$ 5.8829
(78.81%)
1.3M
ZPTAZapata Computing Holdings Inc
$ 0.742
(37.41%)
2.75M
NUVOHoldco Nuvo Group DG Ltd
$ 0.87
(23.76%)
100.35k
IVAInventiva SA
$ 2.76
(21.05%)
1.33k
DXCMDexCom Inc
$ 68.00
(-36.95%)
5.63M
ADNAdvent Technologies Holdings Inc
$ 3.40
(-30.61%)
9.92k
ZYXIZynex Inc
$ 7.9897
(-21.59%)
29.19k
RLAYRelay Therapeutics Inc
$ 7.15
(-21.08%)
27.83k
PCSAProcessa Pharmaceuticals Inc
$ 1.42
(-14.52%)
114
BFIBurgerFi International Inc
$ 0.4826
(126.47%)
17.38M
SPECSpectaire Holdings Inc
$ 0.4448
(11.20%)
6.56M
DXCMDexCom Inc
$ 68.00
(-36.95%)
5.63M
NVDANVIDIA Corporation
$ 112.31
(0.03%)
5.37M
SLNASelina Hospitality PLC
$ 0.0391
(3.99%)
5.24M

AQST Discussion

View Posts
52172 52172 1 day ago
Not true
👍️0
Sierra20 Sierra20 1 week ago
Nothing. No updates on Libervant after approval. Now Anaphylm won’t be available for 2 more years.
👍️0
52172 52172 3 weeks ago
Keep dropping were not done buying!
👍️0
52172 52172 3 weeks ago
Huge buy opp!
👍️0
Sierra20 Sierra20 2 months ago
It’s heading back to $2. Stop the bleeding please! drug approved but not ready to sell wtf is that? Next earnings will be brutal.
👍️0
PonkenPlonken PonkenPlonken 3 months ago
added. Great science and beautiful chart.
Offerings became bullish.. dont you know?
👍️0
52172 52172 3 months ago
Is a bargain
👍️0
Monksdream Monksdream 3 months ago
AQST under $5

👍️0
52172 52172 3 months ago
Big turn around imminent
👍️0
52172 52172 4 months ago
Yessir absolutely
👍️0
Monksdream Monksdream 4 months ago
In other words you’re confident about this one from the clinical stage drug discovery sector
👍️0
52172 52172 4 months ago
Not for long
👍️0
Monksdream Monksdream 4 months ago
AQST under $5
👍️0
glenn1919 glenn1919 4 months ago
AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
AQST new 52 week hi
👍️0
glenn1919 glenn1919 5 months ago
AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
I HATE YOU NOW..LOL
👍️0
Monksdream Monksdream 5 months ago
AQST new 52 week high
👍️0
glenn1919 glenn1919 5 months ago
AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
52172 52172 5 months ago
Headed much higher!
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST..EXIT...MASSIVE PLAY
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST...BREAKING 4 BUCKS...BEAST
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST monster bio by the master trend
👍️0
glenn1919 glenn1919 5 months ago
AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
AQST new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AQST...NEXT BIO WEEKLY BEAST
👍️0
52172 52172 5 months ago
Just the beginning
👍️0
Monksdream Monksdream 6 months ago
AQST new 52 week high
👍️0
Sierra20 Sierra20 6 months ago
Offering coming probably soon.
👍️0
Monksdream Monksdream 6 months ago
AQST new 52 week high
👍️0
shankapotamus shankapotamus 1 year ago
Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.
👍️0
trendzone trendzone 2 years ago
Toxic slobs is more like it.
👍️0
crudeoil24 crudeoil24 2 years ago
On going S-3 shelf placement!

AQST
👍️0
crudeoil24 crudeoil24 2 years ago
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=aqst%20&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 2 years ago
me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
like this
👍️0
The Night Stalker The Night Stalker 2 years ago
strange POS
👍️0
The Night Stalker The Night Stalker 2 years ago
strange POS
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/aquestive-therapeutics-AQST/stock-news/88375724/aquestive-therapeutics-reports-positive-initial-to
👍️0
Chrisny73 Chrisny73 3 years ago
Quite the hair cut since the delay. I bought in at 4.38 and will buy more if it drops further
👍️0
Jake L Jake L 3 years ago
AQST - FDA Approval Insight

👍️0
Jake L Jake L 3 years ago
AQST - Tuesday Rundown, Wednesday Expectations

👍️0
Aarin Aarin 3 years ago
Parabolic chart for $AQST. PDUFA is on deck.

👍️0
Jake L Jake L 3 years ago
AQST - Update

👍️0
Jake L Jake L 3 years ago
AQST - Tuesday Rundown, Wednesday Expectations

👍️0
Jake L Jake L 3 years ago
AQST - Update

👍️0

Your Recent History

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved